Your browser doesn't support javascript.
loading
Discrimination between Pancreatic Cancer, Pancreatitis and Healthy Controls Using Urinary Polyamine Panel.
Nissinen, Samuli I; Venäläinen, Markus; Kumpulainen, Pekka; Roine, Antti; Häkkinen, Merja R; Vepsäläinen, Jouko; Oksala, Niku; Rantanen, Tuomo.
Afiliação
  • Nissinen SI; Department of Internal Medicine, School of Medicine, 205537University of Eastern Finland, Kuopio, Finland.
  • Venäläinen M; Department of Internal Medicine, 3701Kanta-Häme Central Hospital, Hämeenlinna, Finland.
  • Kumpulainen P; Department of Internal Medicine, School of Medicine, 205537University of Eastern Finland, Kuopio, Finland.
  • Roine A; 60670Tampere University Hospital, Tampere, Finland.
  • Häkkinen MR; Faculty of Medicine and Health Technology, 7840Tampere University, Tampere, Finland.
  • Vepsäläinen J; School of Pharmacy, Biocenter Kuopio, 205537University of Eastern Finland, Kuopio, Finland.
  • Oksala N; School of Pharmacy, Biocenter Kuopio, 205537University of Eastern Finland, Kuopio, Finland.
  • Rantanen T; Faculty of Medicine and Health Technology, 7840Tampere University, Tampere, Finland.
Cancer Control ; 28: 10732748211039762, 2021.
Article em En | MEDLINE | ID: mdl-35135363
ABSTRACT
BACKROUND Polyamines play an important role in cellular proliferation, and the change in polyamine metabolism is reported in various cancers. We searched for urinary polyamine signature for distinguishing between pancreatic cancer, premalignant lesions of the pancreas (PLP), acute and chronic pancreatitis, and controls.

METHODS:

Patients and controls were prospectively recruited in three Finnish hospitals between October 2013 and June 2016. The patients provided a urine sample at the time of the diagnosis. The panel of 14 polyamines was obtained in a single run with mass spectrometry. The polyamine concentrations were analysed with quadratic discriminant analysis and cross-validated with leave-one-out cross-validation.

RESULTS:

Sixty-eight patients with pancreatic cancer, 36 with acute pancreatitis, 18 with chronic pancreatitis and 7 with PLP were recruited, as were 53 controls. The combination of 4 polyamines - acetylputrescine, diacetylspermidine, N8-acetylspermidine and diacetylputrescine - distinguished pancreatic cancer and PLP from controls (sensitivity = 94%, specificity = 68% and AUC = 0.88). The combination of diacetylspermidine, N8-acetylspermidine and diacetylspermine distinguished acute pancreatitis from controls (sensitivity = 94%, specificity = 92%, AUC = 0.98). The combination of acetylputrescine, diacetylspermidine and diacetylputrescine distinguished chronic pancreatitis from controls (sensitivity = 98%, specificity = 71%, AUC = 0.93).

CONCLUSIONS:

Optimally selected urinary polyamine panels discriminate between pancreatic cancer and controls, as well as between acute and chronic pancreatitis and controls.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Pancreatite Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Pancreatite Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article